1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  02:00 2022-07-01 am EDT
5691.00 JPY   -0.59%
06/24Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
AQ
06/22PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
AQ
06/22Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
5620(c) 5712(c) 5800(c) 5725(c) 5691(c) Last
851 000 813 000 1 479 700 1 156 000 783 500 Volume
+1.06% +1.64% +1.54% -1.29% -0.59% Change
More quotes
Estimated financial data (e)
Sales 2022 734 B 5 430 M 5 430 M
Net income 2022 56 199 M 416 M 416 M
Net cash position 2022 143 B 1 060 M 1 060 M
P/E ratio 2022 27,5x
Yield 2022 2,81%
Sales 2023 704 B 5 203 M 5 203 M
Net income 2023 50 890 M 376 M 376 M
Net cash position 2023 226 B 1 671 M 1 671 M
P/E ratio 2023 31,6x
Yield 2023 2,83%
Capitalization 1 632 B 12 070 M 12 070 M
EV / Sales 2022 2,03x
EV / Sales 2023 2,00x
Nbr of Employees 11 322
Free-Float 87,9%
More Financials
Company
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%). 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Ratings of Eisai Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about EISAI CO., LTD.
06/24Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglect..
AQ
06/22PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Regi..
AQ
06/22Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed ..
AQ
06/07EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..
PU
06/06Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 202..
AQ
06/05EISAI PRESENTS NEW FINDINGS FOR ANTI : #5513)Poster Presentation Features Analyses Based o..
PU
06/03Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
AQ
05/30Eisai to Acquire Remaining 15% of Consolidated Unit
MT
05/30EISAI : Announcement of a Summary Share Exchange (kan'i kabushiki kokan) to Make Sunplanet..
PU
05/27Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
AQ
05/27EISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formula..
AQ
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/20EISAI : “MOVICOL® HD” LaunchedA New Dosage Form Added to Polyethylene Glycol C..
PU
05/19Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritora..
CI
05/16Eisai Reiterates Year-end Dividend on Higher FY22 Profit, Revenue as Global Brands Cont..
MT
More news
News in other languages on EISAI CO., LTD.
05/23BROADCOM VISE VMWARE, AIRBUS ÉPARGNE : la revue de presse du lundi 23 mai 2022
05/19La Coalition mondiale pour la recherche adaptative annonce l'arrêt de l'évaluation d'Er..
05/16Eisai réitère son dividende de fin d'année en raison de l'augmentation du bénéfice et d..
05/12Nitto Denko Corporation fournit des prévisions de bénéfices consolidés pour l'année fis..
05/12Eisai Co., Ltd. annonce le versement d'un dividende de fin d'année pour l'exercice clos..
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 5 691,00 JPY
Average target price 5 784,62 JPY
Spread / Average Target 1,64%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Manager-Pharmaceutical Affairs
Lynn D. Kramer President-Neuroscience Drug Discovery Unit
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-12.34%12 081
JOHNSON & JOHNSON3.46%467 100
PFIZER, INC.-13.73%294 179
ELI LILLY AND COMPANY16.94%291 859
ROCHE HOLDING AG-15.97%272 586
ABBVIE INC.13.12%270 651